HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Thymoma — Clinical Guidelines

Overview

Thymoma is a neoplasm arising from the epithelial cells of the thymus, often classified based on its histological characteristics into cortical, medullary, mixed, and other subtypes. These tumors can range from benign to malignant, with varying clinical implications depending on their stage and invasiveness 1 10 12.

Diagnosis

Fine-needle aspiration biopsy (FNAB): Useful for minimally invasive diagnosis, guided by imaging techniques 1.

Histological examination: Essential for definitive diagnosis, often requiring immunohistochemical staining to differentiate subtypes 10 12.

Digital microscopy and whole slide imaging: Enhances reproducibility among pathologists in classifying thymic lesions 4 6.

Imaging studies: CT and MRI aid in staging and assessing extent of disease 2.

Management

Surgical resection: Primary treatment for localized thymomas, with robotic techniques showing promise in minimally invasive approaches 2.

Postoperative radiotherapy (PORT): Recommended for completely resected Masaoka/Masaoka-Koga stage II/III thymomas to improve overall survival 3.

Adjuvant therapy: Not specified in detail within the provided abstracts, but may be considered based on tumor stage and histology 3.

Special Populations

Comorbidities: No specific guidance provided in the abstracts regarding management adjustments for comorbidities like systemic lupus erythematosus associated with thymoma 14.

Elderly: No explicit recommendations tailored for elderly patients; surgical risks and tolerance to adjuvant therapies should be carefully considered 2.

Key Recommendations

Perform surgical resection for localized thymomas as the primary treatment approach 2.

Consider postoperative radiotherapy for completely resected Masaoka/Masaoka-Koga stage II/III thymomas to enhance survival outcomes 3 (Evidence: Strong).

Utilize fine-needle aspiration biopsy guided by imaging for preoperative diagnosis 1 (Evidence: Moderate).

Employ immunohistochemical staining in histological examination to accurately classify thymoma subtypes 10 12 (Evidence: Moderate).

Evaluate thymoma using digital microscopy to improve diagnostic consistency among pathologists 4 6 (Evidence: Moderate).

References

1 Cozzolino I, Calaminici M, Ronchi A, Ehinger M, Al-Abbadi MA, Barroca H et al.. The World Health Organization Reporting System for Lymph Node, Spleen, and Thymus Cytopathology: Part 2 - Spleen and Thymus. Acta cytologica 2026. link 2 Shimomura M, Okada S, Furuya T, Oya R, Hirakawa Y, Amaya F et al.. Short-term outcomes of robotic subxiphoid-optical thymectomy. Surgery today 2025. link 3 Tateishi Y, Horita N, Namkoong H, Enomoto T, Takeda A, Kaneko T. Postoperative Radiotherapy for Completely Resected Masaoka/Masaoka-Koga Stage II/III Thymoma Improves Overall Survival: An Updated Meta-Analysis of 4746 Patients. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2021. link 4 Wolf JL, van Nederveen F, Blaauwgeers H, Marx A, Nicholson AG, Roden AC et al.. Interobserver variation in the classification of thymic lesions including biopsies and resection specimens in an international digital microscopy panel. Histopathology 2020. link 5 Nicholson AG, Detterbeck F, Marx A, Roden AC, Marchevsky AM, Mukai K et al.. Dataset for reporting of thymic epithelial tumours: recommendations from the International Collaboration on Cancer Reporting (ICCR). Histopathology 2017. link 6 Wang H, Sima CS, Beasley MB, Illei P, Saqi A, Nonaka D et al.. Classification of thymic epithelial neoplasms is still a challenge to thoracic pathologists: a reproducibility study using digital microscopy. Archives of pathology & laboratory medicine 2014. link 7 Veynovich B, Masetti P, Kaplan PD, Jasnosz KM, Yousem SA, Landreneau RJ. Primary pulmonary thymoma. The Annals of thoracic surgery 1997. link00935-1) 8 Knecht JW. Cancer in inguinal hernias. New Jersey medicine : the journal of the Medical Society of New Jersey 1990. link 9 Dardenne M, Savino W, Bach JF. Thymomatous epithelial cells and skeletal muscle share a common epitope defined by a monoclonal antibody. The American journal of pathology 1987. link 10 Eimoto T, Teshima K, Shirakusa T, Takeshita M, Okamura H, Naito H et al.. Heterogeneity of epithelial cells and reactive components in thymomas: an ultrastructural and immunohistochemical study. Ultrastructural pathology 1986. link 11 Finley JL, Silverman JF, Strausbauch PH, Dabbs DJ, West RL, Weaver MD et al.. Malignant thymic neoplasms: diagnosis by fine-needle aspiration biopsy with histologic, immunocytochemical, and ultrastructural confirmation. Diagnostic cytopathology 1986. link 12 Müller-Hermelink HK, Marino M, Palestro G, Schumacher U, Kirchner T. Immunohistological evidences of cortical and medullary differentiation in thymoma. Virchows Archiv. A, Pathological anatomy and histopathology 1985. link 13 Collins JD, Pagani JJ. Thymoma metastatic to bone. Journal of the National Medical Association 1979. link 14 Simeone JF, McCloud T, Putman CE, Marsh J. Thymoma and systemic lupus erythematosus. Thorax 1975. link 15 Jacobs EM. Benign thymoma and selective erythroid aplasia of the bone marrow. California medicine 1967. link

Thymoma